Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 3:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 201 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: LMWH (Fragmin, dalteparin) Clear all
Completed No phase listed Observational

Evaluation of the Accuracy of the INRatio Prothrombin Time (PT) Monitoring System With a New Test Strip for the Oral Anticoagulation Therapy Patient in the Presence of Heparin and Low Molecular Weight Heparin (e.g., Enoxaparin or Dalteparin)

NCT00933738
View directory record Official record
Conditions
Coagulation
Interventions
Not listed
Lead sponsor
Abbott RDx Cardiometabolic
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
12
States / cities
Loma Linda, California • Aurora, Colorado • Detroit, Michigan + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2011 · Synced Oct 17, 2026, 3:17 AM EDT
Not yet recruiting Phase 3 Interventional

Collaborative Risk-stratified Investigation in Thrombosis-prone Inpatients With Critical Illness: Anticoagulation With LMWH in Teens for ThromboProphylaxis (CRITICAL-Teens-TP).

NCT06628778
View directory record Official record
Conditions
Venous Thromboembolism (VTE)
Interventions
Enoxaparin
Drug
Lead sponsor
Johns Hopkins All Children's Hospital
Other
Eligibility
12 Years to 18 Years
Enrollment
802 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2035
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 17, 2026, 3:17 AM EDT
Completed Phase 4 Interventional Results available

Management of Superficial Thrombophlebitis

NCT00264381
View directory record Official record
Conditions
Superficial Thrombophlebitis, Upper Extremity Superficial Thrombophlebitis, Lower Extremity Superficial Thrombophlebitis
Interventions
Dalteparin sodium injection
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
2
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Nov 18, 2013 · Synced Oct 17, 2026, 3:17 AM EDT
Completed Phase 2 Interventional Results available

Pilot Study of Rosuvastatin and Enoxaparin Thromboprophylaxis Following Ovarian Cancer Surgery (O-STAT Study)

NCT03532139
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Enoxaparin, Enoxaparin + Rosuvastatin, Thromboprophylaxis
Drug · Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 17, 2026, 3:17 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype

NCT02589145
View directory record Official record
Conditions
Lymphoma
Interventions
Lenalidomide, Vorinostat, Gemcitabine, Busulfan, Melphalan, Rituximab, Dexamethasone, Caphosol, Glutamine, Pyridoxine, Enoxaparin, Stem Cell Transplant, Palifermin
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
15 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 13, 2019 · Synced Oct 17, 2026, 3:17 AM EDT
Terminated Phase 3 Interventional Results available

Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With Dexamethasone

NCT00522392
View directory record Official record
Conditions
Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
Interventions
bortezomib, lenalidomide, dexamethasone
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
275
States / cities
Scottsdale, Arizona • Fairfield, California • San Diego, California + 184 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2015 · Synced Oct 17, 2026, 3:17 AM EDT
Completed No phase listed Observational

Replication of the RECORD1 Anticoagulant Trial in Healthcare Claims Data

NCT05083455
View directory record Official record
Conditions
Deep Vein Thrombosis, Pulmonary Embolus
Interventions
Rivaroxaban, Enoxaparin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 120 Years
Enrollment
89,215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 17, 2026, 3:17 AM EDT
Terminated Not applicable Interventional Results available

Evaluating the Use of Thromboelastography (TEG) in Patient's Requiring Extracorporeal Membrane Oxygenation (ECMO)

NCT02887820
View directory record Official record
Conditions
Heart Disease, Lung Disease
Interventions
Thromboelastograph
Device
Lead sponsor
Stephen Esper
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 31, 2025 · Synced Oct 17, 2026, 3:17 AM EDT
Terminated Phase 4 Interventional Results available

Low-Dose Tenecteplase in Covid-19 Diagnosed With Pulmonary Embolism

NCT04558125
View directory record Official record
Conditions
Pulmonary Embolism, COVID
Interventions
TNKase, Placebo, Enoxaparin
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 26, 2021 · Synced Oct 17, 2026, 3:17 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Apixaban vs Enoxaparin Following Microsurgical Breast Reconstruction-An RCT

NCT04504318
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Apixaban 2.5 MG Oral Tablet, Enoxaparin 40Mg/0.4mL Prefilled Syringe
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 89 Years · Female only
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 22, 2025 · Synced Oct 17, 2026, 3:17 AM EDT
Completed No phase listed Observational

Observational Studies in Cancer Associated Thrombosis for Rivaroxaban - United States Cohort

NCT04979780
View directory record Official record
Conditions
Treatment of Venous Thromboembolism in Cancer Patients, Prophylaxis of Recurrent Venous Thromboembolism in Cancer Patients
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Low molecular weight heparin (LMWH), Direct Oral Anticoagulants (DOAC)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
3,708 participants
Timeline
2021 – 2022
U.S. locations
1
States / cities
Multiple Locations, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 31, 2024 · Synced Oct 17, 2026, 3:17 AM EDT
Completed Phase 3 Interventional Results available

Study of Apixaban for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery

NCT00371683
View directory record Official record
Conditions
Deep Vein Thrombosis, Pulmonary Embolism
Interventions
Enoxaparin + Placebo, Apixaban + Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
3,608 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
25
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Little Rock, Arkansas + 17 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2015 · Synced Oct 17, 2026, 3:17 AM EDT
Completed Phase 3 Interventional Results available

Cancer Venous Thromboembolism (VTE)

NCT02073682
View directory record Official record
Conditions
Venous Thromboembolism (VTE), Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Cancer
Interventions
Edoxaban, Dalteparin, Low molecular weight heparin
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
1,046 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
4
States / cities
Brandon, Florida • Jonesboro, Georgia • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2019 · Synced Oct 17, 2026, 3:17 AM EDT
Completed Not applicable Interventional Results available

Aspirin and Compression Devices for VTE Prophylaxis in Orthopaedic Oncology

NCT01696760
View directory record Official record
Conditions
Bone Metastases, Musculoskeletal Cancer, Soft Tissue Sarcoma, Thromboembolism
Interventions
acetylsalicylic acid, enoxaparin, PCD
Drug · Device
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 5, 2018 · Synced Oct 17, 2026, 3:17 AM EDT
Completed Phase 4 Interventional Results available

Apixaban for the Acute Treatment of Venous Thromboembolism in Children

NCT02464969
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Apixaban, Standard of Care
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
0 Days to 17 Years
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
84
States / cities
Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 47 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2024 · Synced Oct 17, 2026, 3:17 AM EDT
Completed Phase 2 Interventional Results available

COVID-19 Anticoagulation in Children - Thromboprophlaxis (COVAC-TP) Trial

NCT04354155
View directory record Official record
Conditions
Infection Viral, Thromboses, Venous, COVID-19
Interventions
Enoxaparin Prefilled Syringe [Lovenox]
Drug
Lead sponsor
Johns Hopkins All Children's Hospital
Other
Eligibility
0 Years to 18 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
16
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2022 · Synced Oct 17, 2026, 3:17 AM EDT
Recruiting No phase listed Observational

Circadian Variation of Anti-Factor Xa in Hospitalized Trauma Patients

NCT07856641
View directory record Official record
Conditions
Circadian Variation in Anti-Factor Xa (Anti-FXa) Activity
Interventions
Not listed
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 17, 2026, 3:17 AM EDT
Completed Not applicable Interventional Results available

Once Weekly Subcutaneous Ports for the Administration of Anticoagulants

NCT00774748
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Insuflon
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 23, 2017 · Synced Oct 17, 2026, 3:17 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy Trial Evaluating the Use of SR34006 in the Treatment of Deep Vein Thrombosis (DVT)

NCT00067093
View directory record Official record
Conditions
Deep Vein Thrombosis
Interventions
SanOrg34006, LMW heparin, Unfractionated heparin, Vitamin K antagonist (VKA)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
1,452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
24
States / cities
Denver, Colorado • Jacksonville, Florida • Melbourne, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2011 · Synced Oct 17, 2026, 3:17 AM EDT
Completed Phase 3 Interventional Results available

Study of Apixaban for the Prevention of Thrombosis-related Events in Patients With Acute Medical Illness

NCT00457002
View directory record Official record
Conditions
Venous Thrombosis, Pulmonary Embolism
Interventions
Apixaban, Enoxaparin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
40 Years and older
Enrollment
6,758 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
48
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 42 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2015 · Synced Oct 17, 2026, 3:17 AM EDT
Completed Phase 2 Interventional Results available

Fixed Versus Weight-Based Enoxaparin Dosing in Thoracic Surgery Patients

NCT03251963
View directory record Official record
Conditions
Venous Thromboembolism, Deep Venous Thrombosis, Surgery
Interventions
Fixed Dose Enoxaparin, Variable Dose Enoxaparin
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 8, 2020 · Synced Oct 17, 2026, 3:17 AM EDT
Terminated Phase 4 Interventional Results available

Below Knee DVT Study

NCT03805672
View directory record Official record
Conditions
Deep Vein Thrombosis (DVT), Blood Clots
Interventions
Low Dose Enoxaparin, High Dose Enoxaparin
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 13, 2019 · Synced Oct 17, 2026, 3:17 AM EDT
Terminated Phase 2 Interventional

Heparin Anticoagulation in Septic Shock

NCT03378466
View directory record Official record
Conditions
Septic Shock, Vasodilatory Shock
Interventions
Unfractionated heparin, Venous thromboprophylaxis (VTE)
Drug · Other
Lead sponsor
University of Manitoba
Other
Eligibility
18 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 24, 2022 · Synced Oct 17, 2026, 3:17 AM EDT
Completed Phase 3 Interventional Results available

Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Hip Replacement Surgery (ADVANCE-3)

NCT00423319
View directory record Official record
Conditions
Deep Vein Thrombosis, Pulmonary Embolism
Interventions
Enoxaparin, Apixaban, Enoxaparin-matching placebo, Apixaban-matching placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
5,407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
19
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Sacramento, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 14, 2014 · Synced Oct 17, 2026, 3:17 AM EDT